INSM AI Stock Analysis – Buy, Hold, or Avoid?
Insmed Incorporated (INSM)
Insmed (INSM) offers exceptional revenue growth and pipeline potential but faces persistent losses, high leverage, and recent technical and sentiment deterioration. While long-term prospects are strong if pipeline milestones are met, near-term risks and volatility are elevated, making the stock suitable only for risk-tolerant investors. The investment case is highly time-frame dependent, with short-term caution warranted and long-term upside possible.
Fundamentals
Insmed Incorporated is displaying accelerating top-line growth, with quarterly revenues showing notable year-over-year expansion. However, the company continues to operate with significant losses, as heavy R&D and SG&A investment weigh on bottom-line results. While revenue momentum is robust, persistent negative earnings and cash flow are key concerns for long-term sustainability.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
229.62% YoY
Q1 2026
Net Income
36.25% YoY
Q1 2026
Net Margin
Q1 2026
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q1 2026
Net Income Growth YoY
Latest Quarter: Q1 2026
Revenue Per Share Growth YoY
Latest Quarter: Q1 2026
EPS Growth YoY
Latest Quarter: Q1 2026
Book Value Per Share Growth YoY
Latest Quarter: Q1 2026
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 306.0M | 263.8M | 142.3M | 107.4M | 92.8M | 104.4M | 93.4M | 90.3M |
| Revenue Growth YoY | +229.62% | +152.62% | +52.36% | +18.90% | +22.94% | +24.79% | +18.15% | +16.98% |
| Net Income | -163.6M | -328.5M | -370.0M | -321.7M | -256.6M | -235.5M | -220.5M | -300.6M |
| Net Income Growth YoY | +36.25% | -39.46% | -67.79% | -7.01% | -63.33% | -26.60% | -38.75% | -22.79% |
| EPS | -$0.76 | -$1.54 | -$1.75 | -$1.70 | -$1.42 | -$1.32 | -$1.27 | -$1.94 |
| EPS Growth YoY | +46.48% | -16.67% | -37.80% | +12.37% | -33.96% | -3.13% | -14.41% | -8.99% |
Profitability Metrics
Gross Margin
TTM
Operating Margin
TTM
Net Margin
TTM
Return on Equity
TTM
Return on Assets
TTM
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.82% | 83.24% | 79.37% | 73.86% | 77.08% | 74.96% | 77.34% | 76.79% |
| Operating Margin | -65.46% | -94.64% | -257.13% | -291.28% | -267.33% | -220.61% | -228.45% | -319.80% |
| Net Margin | -53.46% | -124.50% | -259.95% | -299.48% | -276.42% | -225.53% | -236.04% | -332.75% |
| Return on Equity (ROE) | -23.21% | -44.45% | -39.13% | -25.74% | -258.76% | -82.54% | -45.62% | -774.41% |
| Return on Assets (ROA) | -8.87% | -16.18% | -17.29% | -14.06% | -15.94% | -12.87% | -11.88% | -18.64% |
Technical Analysis
INSM is currently in a strong downtrend with price well below key moving averages, confirmed by a death cross and high ADX indicating strong trend momentum. RSI reflects oversold conditions, signaling potential for a short-term bounce, although the stock remains in a consolidation phase without a clear reversal yet.
No extreme reading
Price in downtrend
Strong trend active
50 below 200 - bearish
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Insmed Incorporated is displaying accelerating top-line growth, with quarterly revenues showing notable year-over-year expansion. However, the company continues to operate with significant losses, as heavy R&D and SG&A investment weigh on bottom-line results. While revenue momentum is robust, persistent negative earnings and cash flow are key concerns for long-term sustainability.
Latest Earnings
Q1 2026 Earnings (Mar 31, 2026)
Earnings Per Share (EPS)
Actual
$-0.76
Estimated
$-0.90
Surprise
+$0.14
Surprise %
+15.56%
Revenue
Actual
$305.96M
Estimated
$300.81M
Surprise
+$5.15M
Surprise %
+1.71%
Historical Earnings
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $-0.76 | $-1.54 | $-1.75 | $-1.70 | $-1.42 | $-1.32 | $-1.27 | $-1.94 |
| EPS (Estimated) | $-0.90 | $-1.07 | $-1.33 | $-1.30 | $-1.34 | $-1.17 | $-1.20 | $-1.24 |
| EPS Surprise | +$0.14 | -$0.47 | -$0.42 | -$0.40 | -$0.08 | -$0.15 | -$0.07 | -$0.70 |
| % Diff | +15.6% | -43.9% | -31.6% | -30.8% | -6.0% | -12.8% | -5.8% | -56.5% |
| Revenue | ||||||||
| Revenue (Actual) | $305.96M | $263.84M | $142.34M | $107.42M | $92.82M | $104.44M | $93.43M | $90.34M |
| Revenue (Estimated) | $300.81M | $231.25M | $115.45M | $104.13M | $91.47M | $102.08M | $93.36M | $87.95M |
| Revenue Surprise | +$5.15M | +$32.6M | +$26.9M | +$3.29M | +$1.36M | +$2.36M | +$64.13K | +$2.39M |
| % Diff | +1.7% | +14.1% | +23.3% | +3.2% | +1.5% | +2.3% | +0.1% | +2.7% |
Valuation
Insmed Inc. is trading at a significant premium relative to its biotech peers, supported by strong revenue growth and highly positive analyst sentiment. Despite ongoing losses, the market is pricing in substantial future growth and pipeline success, reflected in its elevated valuation multiples and bullish price target consensus.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | -53.85 | -28.30 | -20.60 | -14.81 | -13.44 | -13.12 | -14.38 | -8.54 |
| Price to Sales | 115.16 | 140.92 | 214.24 | 177.36 | 148.65 | 118.34 | 135.74 | 113.60 |
| Price to Book | 49.99 | 50.31 | 32.25 | 15.24 | 139.15 | 43.31 | 26.23 | 264.39 |
| Enterprise Value to EBITDA | -181.92 | -123.91 | -89.41 | -62.30 | -63.17 | -61.96 | -68.13 | -37.54 |
| Enterprise Value to Revenue | 115.70 | 141.90 | 217.12 | 172.33 | 158.41 | 125.61 | 143.26 | 115.07 |
Sentiment & Analyst Ratings
Insmed's market sentiment is currently mixed but leans positive due to strong analyst confidence and high price targets supported by promising drug sales and a robust pipeline. However, recent earnings results missed sales consensus and triggered a sharp stock price decline with notable insider selling, contributing to caution among investors. Social media buzz is bullish but reflects division among retail sentiment.
Analyst Recommendations
Risk Assessment
Insmed Incorporated exhibits a mixed risk profile characterized by strong liquidity but elevated leverage and significant net losses. Despite robust revenue growth driven by recent drug launches, profitability remains a challenge with deep negative earnings, and the company faces operational risks from clinical setbacks and regulatory uncertainties. Investors should weigh the promising market potential against ongoing execution and financial sustainability risks.
Liquidity & Solvency
Current Ratio
Latest Quarter: Q1 2026
Quick Ratio
Latest Quarter: Q1 2026
Debt-to-Equity
Latest Quarter: Q1 2026
Debt-to-Assets
Latest Quarter: Q1 2026
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Liquidity Metrics | ||||||||
| Current Ratio | 4.47 | 3.83 | 4.63 | 6.68 | 5.86 | 5.45 | 6.37 | 2.71 |
| Quick Ratio | 4.10 | 3.54 | 4.34 | 6.33 | 5.44 | 5.12 | 5.99 | 2.53 |
| Solvency Metrics | ||||||||
| Debt-to-Equity | 1.06 | 1.04 | 0.79 | 0.59 | 13.21 | 4.60 | 2.41 | 35.53 |
| Debt-to-Assets | 0.36 | 0.34 | 0.32 | 0.30 | 0.73 | 0.65 | 0.57 | 0.76 |
Liquidity Assessment
Current Ratio: 4.47(Strong)
Quick Ratio: 4.10(Strong)
The company has strong liquidity with sufficient short-term assets to cover liabilities.
Solvency Assessment
Debt-to-Equity: 1.06(High)
Debt-to-Assets: 0.36(Moderate)
The company has relatively high debt levels, which may increase financial risk in economic downturns.
Frequently Asked Questions about INSM
AI Answers: Common Questions About INSM
Get AI-powered answers to the questions investors ask most about Insmed Incorporated
INSM is not a clear buy at current levels for most investors. The stock trades at a significant premium (negative P/E of -17.6, high P/S and P/B), is in a strong downtrend, and sentiment has deteriorated after a 23% post-earnings drop. Only long-term, risk-tolerant investors should consider buying, and even then, position sizing should be conservative.
If you are a short-term trader or uncomfortable with high volatility, selling or reducing exposure is prudent given the strong downtrend, technical breakdown (death cross, RSI 21), and recent insider selling. Long-term investors with conviction in the pipeline may choose to hold through volatility, but should monitor for further fundamental or technical deterioration.
The biggest risks are clinical/regulatory failures (which could erase much of the premium valuation), ongoing net losses (net margin near -53%, negative EV/EBITDA), and high leverage (debt-to-equity above 1). Insider selling and earnings misses have increased volatility and downside risk.
Analyst targets are bullish, ranging from $140 to over $200 (40-100% upside), but technical resistance lies at $144 (50 SMA) and $155 (200 SMA). Downside risk extends to the 52-week low of $63.81 if support fails.
The stock is overvalued relative to peers, with a negative P/E (-17.6), high price-to-sales, and negative EV/EBITDA, meaning the market is pricing in substantial future growth and pipeline success. If growth or pipeline milestones are missed, the valuation could compress sharply.
Fundamentally, INSM is strong on revenue growth (230% YoY in Q1 2026), gross margins (84%+), and niche market leadership, but remains deeply unprofitable with persistent net losses and high R&D/SG&A spend. Liquidity is strong (current ratio >3.8), but leverage is rising.
Technically, the stock is in a pronounced downtrend with a death cross active, price well below all major moving averages, and RSI at 21 indicating oversold conditions. No reversal pattern is present; support is at $63.81, resistance at $144 and $155.
Key catalysts include upcoming late-stage clinical trial results, regulatory decisions, and quarterly earnings. Positive news could trigger a sharp rebound, while further misses or negative trial outcomes could drive additional downside.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.